TY - JOUR
T1 - Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults
AU - Gonzalez, Idalia M.
AU - Karron, Ruth A.
AU - Eichelberger, Maryna
AU - Walsh, Edward E.
AU - Delagarza, Vincent W.
AU - Bennett, Richard
AU - Chanock, Robert M.
AU - Murphy, Brian R.
AU - Clements-Mann, Mary Lou
AU - Falsey, Ann R.
N1 - Funding Information:
This work was supported by National Institutes of Health (NIH)-NIAID Contract ♯N01-A0-62712 and is part of a continuing program of research and development with Wyeth–Lederle Vaccines and Pediatrics through CRADA No. AI-000030 and AI-000087.
PY - 2000/3/6
Y1 - 2000/3/6
N2 - The safety and immunogenicity of the live attenuated cold-passaged, temperature-sensitive (cpts) 248/404 respiratory syncytial virus (RSV) A2 and the RSV A2 purified F glycoprotein (PFP-2) vaccine candidates were evaluated in a placebo-controlled trial in 60 healthy young adults and 60 healthy elderly subjects using simultaneous and sequential (cpts 248/404 followed by PFP-2) vaccination schedules. Both vaccines were well tolerated. The cpts 248/404 vaccine was moderately infectious in both young and old volunteers, but was highly restricted in replication in those who were infected. After both vaccines, RSV neutralizing antibody (neut Ab) titers increased fourfold in 22% of young subjects and in 16% of elderly subjects. Of those with low levels of RSV neut Ab (titer < 9), 10/12 (83% of) young subjects and six/eight (75% of) elderly subjects had a ≥four fold rise in neut Ab titer. Young and elderly subjects immunized simultaneously had similar serum IgG and IgA postimmunization titers to RSV F (IgG, 16.4 vs 16.2, IgA 11.6 vs 12.5, respectively) as did those who were immunized sequentially (IgG 17.4 vs 17.0, IgA 13.0 vs 13.5). In both age groups, sequential immunization elicited higher postimmunization RSV F IgG and IgA titers than simultaneous immunization. Further studies that combine the PFP-2 subunit vaccine with a less attenuated RSV vaccine should be performed. (C) 2000 Elsevier Science Ltd.
AB - The safety and immunogenicity of the live attenuated cold-passaged, temperature-sensitive (cpts) 248/404 respiratory syncytial virus (RSV) A2 and the RSV A2 purified F glycoprotein (PFP-2) vaccine candidates were evaluated in a placebo-controlled trial in 60 healthy young adults and 60 healthy elderly subjects using simultaneous and sequential (cpts 248/404 followed by PFP-2) vaccination schedules. Both vaccines were well tolerated. The cpts 248/404 vaccine was moderately infectious in both young and old volunteers, but was highly restricted in replication in those who were infected. After both vaccines, RSV neutralizing antibody (neut Ab) titers increased fourfold in 22% of young subjects and in 16% of elderly subjects. Of those with low levels of RSV neut Ab (titer < 9), 10/12 (83% of) young subjects and six/eight (75% of) elderly subjects had a ≥four fold rise in neut Ab titer. Young and elderly subjects immunized simultaneously had similar serum IgG and IgA postimmunization titers to RSV F (IgG, 16.4 vs 16.2, IgA 11.6 vs 12.5, respectively) as did those who were immunized sequentially (IgG 17.4 vs 17.0, IgA 13.0 vs 13.5). In both age groups, sequential immunization elicited higher postimmunization RSV F IgG and IgA titers than simultaneous immunization. Further studies that combine the PFP-2 subunit vaccine with a less attenuated RSV vaccine should be performed. (C) 2000 Elsevier Science Ltd.
KW - Adults
KW - Elderly
KW - Respiratory syncytial virus vaccines
UR - http://www.scopus.com/inward/record.url?scp=0033997580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033997580&partnerID=8YFLogxK
U2 - 10.1016/S0264-410X(99)00527-7
DO - 10.1016/S0264-410X(99)00527-7
M3 - Article
C2 - 10699324
AN - SCOPUS:0033997580
SN - 0264-410X
VL - 18
SP - 1763
EP - 1772
JO - Vaccine
JF - Vaccine
IS - 17
ER -